Healthleap Raises $38 Million Across Seed and Series A for AI That Flags Hospital Patients With Hidden Diagnoses

Hospitals often miss patients whose conditions are not obvious from a single note or lab result. Healthleap, a San Francisco startup, has built software that reads across a patient's records to flag them, and it raised $38 million across a seed round and a Series A.

The $8 million seed round was co-led by Sequoia Capital and First Round Capital, and the $30 million Series A was led by Hummingbird Ventures. The company is not disclosing its valuation.

What the Product Does

Healthleap reviews clinical notes, lab results, vital signs, orders and problem lists, then delivers risk scores inside the electronic health record tools that clinicians already use. It looks for phrases such as poor appetite or trouble swallowing and combines them with labs, vitals and medications. The company presents itself as an administrative safety net and not as an automated diagnosis tool.

Siblings Jemima and Josiah Meyer founded the company in South Africa in 2022, starting with a clinical nutrition tool Jemima built for dietitians. It now screens adult inpatients daily at more than 50 hospitals, including Penn Medicine, Houston Methodist, Cedars-Sinai and Emory Healthcare. It has expanded from malnutrition to delirium, aspiration pneumonia, pressure ulcers and heart failure readmission risk.

Company Claims to Treat With Caution

Josiah Meyer said revenue has grown more than ten times over the same period, and the company says its malnutrition program at Penn generated $23.8 million in annualized financial impact. Those figures are the company's own, and the reporting does not show how the Penn number was measured or audited.

Why Hospitals Care

Hospital teams already face heavy workloads, and conditions such as malnutrition or delirium can go unrecorded when no single clinician sees the whole picture. A tool that reads records the hospital already has, and sends a risk score into the system clinicians already use, asks for little change in how people work. That is a large part of why this kind of product can spread from one hospital to many. Healthleap's pitch is that earlier flags lead to earlier treatment and lower costs, but the evidence for that sits mostly with the company and its hospital partners, and independent studies would strengthen the case.

The Investor Signal

The round pairs two of the best-known seed investors, Sequoia Capital and First Round Capital, with Hummingbird Ventures on the Series A. Announcing both rounds together suggests the company moved from seed to Series A quickly, and that existing investors had reason to keep supporting it. For founders, the useful part is not the names but the pattern: a narrow first product, a clear buyer, and a path to more conditions within the same customer.

What This Means for Founders

Healthleap started with a narrow tool for one profession and widened to a hospital-wide platform, and early backers funded that path. For health technology founders, the lesson is that fitting into existing clinical software, not replacing it, can speed adoption in a slow-moving market.

If you are raising a Series A, show which hospitals pay and how a first use case leads to more. Combining a seed round and a Series A in one announcement is also a reminder to check how much dilution each stage carries, and to ask each lead investor how it supports sales into large institutions.

Read the baseline mechanics of a limited partner if the term is new, or explore active capital on AngelLinx @ angellinx.ai/register.

AngelLinx Intelligence | angellinx.ai